BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S, Sakaida I. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr. 2016;58:202-209. [PMID: 27257345 DOI: 10.3164/jcbn.15-127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhou H, Chen J, Fan M, Cai H, Dong Y, Qiu Y, Zhuang Q, Lei Z, Li M, Ding X, Yan P, Lin A, Zheng S, Yan Q. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2. J Exp Clin Cancer Res 2023;42:5. [PMID: 36600258 DOI: 10.1186/s13046-022-02562-4] [Reference Citation Analysis]
2 Jomen W, Ohtake T, Akita T, Suto D, Yagi H, Osawa Y, Kohgo Y. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomed Pharmacother 2022;153:113363. [PMID: 35834989 DOI: 10.1016/j.biopha.2022.113363] [Reference Citation Analysis]
3 Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681. [PMID: 32698792 DOI: 10.1186/s12885-020-07167-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
4 Bloomer SA, Brown KE. Iron-Induced Liver Injury: A Critical Reappraisal. Int J Mol Sci 2019;20:E2132. [PMID: 31052166 DOI: 10.3390/ijms20092132] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
5 Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Oncotarget 2018;9:28434-44. [PMID: 29983871 DOI: 10.18632/oncotarget.25421] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
6 Yamada S, Kimura M, Saito Y, Saito H. Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. J Clin Biochem Nutr 2018;63:123-8. [PMID: 30279623 DOI: 10.3164/jcbn.17-125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ma Y, Okazaki Y, Glass J. A fluorescent metal-sensor study provides evidence for iron transport by transcytosis in the intestinal epithelial cells. J Clin Biochem Nutr 2018;62:49-55. [PMID: 29362518 DOI: 10.3164/jcbn.17-74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Nishikawa T, Asai A, Okamoto N, Yasuoka H, Nakamura K, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Tsuda Y, Yamamoto K, Higuchi K. The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients. J Clin Biochem Nutr 2017;61:222-7. [PMID: 29203965 DOI: 10.3164/jcbn.17-57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]